UBS Group’s Legend Biotech LEGN Stock Holding History
Bought
Maintained
Sold
Other funds holding LEGN
KCM
UBS Group's LEGN Position: Q3 2026 in Review
UBS Group increased its Legend Biotech (LEGN) stake by 8% in Q3 2026, buying an estimated $853K and bringing the position to 542,465 shares worth $10.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3323.
UBS Group first reported a position in LEGN in Q2 2020 and has held it in 26 quarters since. The position peaked at $36.3M in Q2 2025. 198 funds tracked by Wall St. Rank hold LEGN as of Q3 2026.
- UBS Group held 542,465 shares of Legend Biotech worth $10.8M as of Q3 2026.
- UBS Group bought 39,999 Legend Biotech shares in Q3 2026, an estimated $853K.
- Legend Biotech made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #3323 holding.
- UBS Group first reported a position in Legend Biotech in Q2 2020 and has held it in 26 quarters since.
- UBS Group's Legend Biotech position peaked at $36.3M in Q2 2025.
- 198 funds tracked by Wall St. Rank held Legend Biotech as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.